Bank of America Securities analyst Jason Gerberry maintained a Sell rating on Organon (OGN – Research Report) today and set a price target of ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

Organon (OGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road ...

Biogen's research organization recently went through an overhaul that company leaders say should allow the Cambridge drugmaker to increase the number of molecules that get into the clinic, and ...

Biogen had a net margin of 16.87% and a return on equity of 14.98%. On average, analysts forecast that Biogen will post 15.83 earnings per share for the current fiscal year. Insider Buying and ...

Shares of Biogen Inc. BIIB shed 3.08% to $119.19 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.23% to 5,062.25 and Dow ...

U.S. pharma imports hit $200 billion in 2024, a 10% tariff could cost the sector $20 billion. Vertex and Alnylam are seen as most resilient to tariff, tax and Medicaid risks. Markets are messy ...

Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved ...

The creator economy is catching notable VCs' attention — and their wallets. Creator-focused startups are raising millions of dollars. Here are the pitch decks that 40 startups used in Series A ...

This information is based on a press release statement from Biogen. In other recent news, Organon has acquired the U.S. regulatory and commercial rights for TOFIDENCE™, a biosimilar to ACTEMRA®, from ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.